Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Aquestive Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 51 | 48 | 51 | 46 | 53 |
Cost Of Goods | 21 | 19 | 15 | 13 | 20 |
Gross Profit | 30 | 28 | 36 | 33 | 32 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 70 | 71 | 76 | 85 |
Income After Depreciation & Amortization | -15 | -42 | -35 | -43 | -53 |
Non-Operating Income | 15 | 0 | -13 | 0 | -4 |
Interest Expense | 7 | 12 | 22 | 13 | 9 |
Pretax Income | -8 | -54 | -71 | -56 | -66 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -54 | -71 | -56 | -66 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -54 | -71 | -56 | -66 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -12 | -39 | -28 | -37 | -48 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 7 | 6 | 5 |
Income After Depreciation & Amortization | -15 | -42 | -35 | -43 | -53 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 61.26 | 48.73 | 38.08 | 33.65 | 25.36 |
Diluted EPS Before Non-Recurring Items | -0.13 | -1.12 | -1.49 | -1.66 | -2.42 |
Diluted Net EPS (GAAP) | -0.13 | -1.12 | -1.85 | -1.66 | -2.61 |
Fiscal Year end for Aquestive Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 20.10 | 12.05 | 13.21 | 13.00 | 13.24 |
Cost Of Goods | 4.53 | 4.39 | 4.68 | 4.80 | 6.62 |
Gross Profit | 15.57 | 7.66 | 8.53 | 8.20 | 6.62 |
SG&A, R&D, and Dept/Amort Expenses | 15.52 | 16.62 | 12.44 | 10.59 | 10.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.05 | -8.96 | -3.91 | -2.39 | -4.21 |
Non-Operating Income | 1.40 | 0.33 | -0.86 | 1.51 | 0.13 |
Interest Expense | 4.20 | 4.20 | 3.24 | 1.31 | 1.43 |
Pretax Income | -2.75 | -12.83 | -8.01 | -2.18 | -5.51 |
Income Taxes | 0.00 | 0.00 | 0.10 | -0.14 | 0.28 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.75 | -12.83 | -8.11 | -2.04 | -5.79 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.75 | -12.83 | -8.11 | -2.04 | -5.79 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 90.91 | 73.62 | 67.20 | 64.68 | 57.35 |
Diluted EPS Before Non-Recurring Items | -0.03 | -0.17 | -0.12 | -0.03 | -0.10 |
Diluted Net EPS (GAAP) | -0.03 | -0.17 | -0.11 | -0.03 | -0.10 |